Stock Events

Stock Events

Lixte Biotechnology 

$4.30
27
-$0.01-0.23% Friday 19:59

Statistics

Day High
4.31
Day Low
4.3
52W High
8.04
52W Low
2.44
Volume
2,758
Avg. Volume
-
Mkt Cap
49.96M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

9MayExpected
Q2 2022
Q3 2022
Q4 2022
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-1
-0.7
-0.39
-0.09
Expected EPS
N/A
Actual EPS
-0.43

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-6.08MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LIXT. It's not an investment recommendation.
NVIDIA
6
NVDA
Coinbase Global
6
COIN
Microsoft
5
MSFT
Tesla
5
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotechnology that could compete with Lixte Biotechnology's cancer and other disease treatments.
Editas Medicine
EDIT
Mkt Cap433.1M
Editas Medicine operates in the genome editing field, directly competing with Lixte's approach to developing treatments for diseases with significant unmet need.
Intellia Therapeutics
NTLA
Mkt Cap1.67B
Intellia Therapeutics is another key player in the CRISPR/Cas9 technology space, potentially competing with Lixte Biotechnology in developing genetic treatments.
Beam Therapeutics
BEAM
Mkt Cap2.76B
Beam Therapeutics uses base editing, a form of gene editing, presenting competition in the precision genetic medicine field relevant to Lixte's interests.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.6B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, competing in the broader biotech space for novel treatments, potentially overlapping with Lixte's focus areas.
Ionis Pharmaceuticals
IONS
Mkt Cap9.51B
Ionis Pharmaceuticals, known for its RNA-targeted drug discovery, competes in the development of novel therapeutics, a market Lixte Biotechnology is also targeting.
Biomarin Pharmaceutical
BMRN
Mkt Cap13.04B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other innovative treatments for rare genetic diseases, competing with Lixte's approach to addressing unmet medical needs.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals, with its focus on treating cystic fibrosis and other serious diseases through novel therapies, represents competition in the biotech innovation space relevant to Lixte Biotechnology.

About

Nomad Power Solutions Inc is a pioneering mobile, utility-grade truck-transportable battery energy storage system. The company's first-to-market products provide one megawatt of instantaneous power to an electrical grid or facility, bypassing months of construction typically required for traditional fixed installations. Its patented platforms, which are deployed on semi-trailers, serve emerging AI-driven applications, along with utilities, industrial operators, government agencies, and critical infrastructure providers through equipment sales, rentals and Energy-as-a-Service offerings. The group's products are Traveler, Voyager Eagle, Voyager Falcon, Voyager Hawk, and Compare Products. Its applications are Utilities, Peak Shaving, EV Charging, and Mining.
Show more...
CEO
Geordan G. Pursglove
Employees
3
Country
United States
ISIN
US5393192027
WKN
000A3EGAA

Listings

STU
DE
8640.STU
MU
DE
864.MU
XNAS
US
NMAD
MU
DE
8640.MU

0 Comments

Share your thoughts

FAQ

What is Lixte Biotechnology stock price today?▼
The current price of LIXT is $4.30 USD — it has decreased by -0.23% in the past 24 hours. Watch Lixte Biotechnology stock price performance more closely on the chart.
What is Lixte Biotechnology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Lixte Biotechnology stocks are traded under the ticker LIXT.
Is Lixte Biotechnology stock price growing?▼
LIXT stock has risen by +10.54% compared to the previous week, the month change is a -31.53% fall, over the last year Lixte Biotechnology has showed a +26.1% increase.
What is Lixte Biotechnology market cap?▼
Today Lixte Biotechnology has the market capitalization of 49.96M
What were Lixte Biotechnology earnings last quarter?▼
LIXT earnings for the last quarter are -0.43 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Lixte Biotechnology revenue for the last year?▼
Lixte Biotechnology revenue for the last year amounts to 0 USD.
What is Lixte Biotechnology net income for the last year?▼
LIXT net income for the last year is -6.08M USD.
How many employees does Lixte Biotechnology have?▼
As of August 23, 2026, the company has 3 employees.
In which sector is Lixte Biotechnology located?▼
Lixte Biotechnology operates in the Health & Wellness sector.
When did Lixte Biotechnology complete a stock split?▼
The last stock split for Lixte Biotechnology was on June 05, 2023 with a ratio of 1:10.
Where is Lixte Biotechnology headquartered?▼
Lixte Biotechnology is headquartered in BOCA RATON, United States.